Results 151 to 160 of about 44,321 (338)

bispecific antibody

Citation: 'bispecific antibody' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.12951 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms ...
openaire   +1 more source

Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier [PDF]

, 2023
William M. Pardridge
openalex   +1 more source

A Transcriptomic Analysis of Cancer‐Stromal Interactome in Lung Cancer Xenograft Models

Cancer Science, EarlyView.
We conducted a comprehensive analysis of the lung cancer interactome to identify key ligand–receptor pairs involved in the aggressiveness of lung adenocarcinoma. Tumor necrosis factor superfamily member 12 and its receptor tumor necrosis factor receptor superfamily member 12A signaling axis may be potential candidates for therapeutic intervention for ...
Yuriko Takayama‐Isagawa, Daisuke Komura, Takayuki Isagawa, Yusuke Amano, Atsushi Kihara, Tamaki Miura, Taichiro Yoshimoto, Hiroyoshi Tsubochi, Kazutaka Fujita, Koichi Hagiwara, Makoto Maemondo, Tetsuo Ushiku, Shumpei Ishikawa, Noriyoshi Fukushima, Kentaro Inamura, Daisuke Matsubara, Toshiro Niki   +16 more
wiley   +1 more source

Identification and engineering of potent bispecific antibodies that protect against herpes simplex virus recurrent disease

Cell Reports
Summary: Herpes simplex virus (HSV) causes lifelong infections, including oral and genital herpes. There is no vaccine, and current antivirals are only partially effective at reducing symptoms and transmission.
Chingwei V. Lee, Hector Viadiu, Apurva Kalamkar, David I. Bernstein, Andrew Pae, Xinchao Yu, Sylvia Wong, Fernando J. Bravo, Sheng Ding, Elbert Seto, Magdeleine Hung, Yu Yu, Weimei Xing, Giuseppe A. Papalia, Wei Kan, Brian Carr, Majlinda Thomas, Leah Tong, Priyanka Desai, Nadine Jarrousse, Alexandre Mercier, Meghan M. Holdorf, Simon P. Fletcher, Emma Abernathy   +23 more
doaj   +1 more source

Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity

, 2014
Koen Wagner, Mark J. Kwakkenbos, Yvonne Claassen, Kelly Maijoor, Martino Böhne, Koenraad F. van der Sluijs, Martin D. Witte, Diana J. van Zoelen, Lisette A. H. M. Cornelissen, Tim Beaumont, Arjen Q. Bakker, Hidde L. Ploegh, Hergen Spits   +12 more
openalex   +2 more sources

Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859

, 2020
National Cancer Institute
openalex   +1 more source

EMB‐01, a Tetravalent Bispecific Antibody, Inducing Co‐Degradation of EGFR and c‐Met for Enhanced Anti‐Tumor Efficacy

Cancer Science, EarlyView.
As the breakthrough bispecific antibody targeting EGFR and c‐Met, EMB‐01 drives potent anti‐tumor efficacy by co‐degradation of both receptors. ABSTRACT The bispecific antibody EMB‐01 (bafisontamab), constructed using EpimAb's proprietary FIT‐Ig platform, is designed to simultaneously target epidermal growth factor receptor (EGFR) and receptor tyrosine
Jing Gao, Xi Jiao, Fang Ren, Xuan Wu, Jingyun Tan, Yuezong Bai, Yan Dai, Lixia Shen, Chengbin Wu, Lin Shen   +9 more
wiley   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

New bispecific antibodies in diffuse large B-cell lymphoma

Haematologica
The CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Adrian G. Minson, Michael J. Dickinson
doaj   +1 more source

Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies [PDF]

Xin Yu, Kostika Vangjeli, Anusha Prakash, Meha Chhaya, Samantha J Stanley, Noah D. Cohen, Lili Huang   +6 more
openalex   +1 more source